| __timestamp | Merck & Co., Inc. | Sarepta Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 11606000000 | 49315000 |
| Thursday, January 1, 2015 | 10313000000 | 75043000 |
| Friday, January 1, 2016 | 9762000000 | 83749000 |
| Sunday, January 1, 2017 | 9830000000 | 122682000 |
| Monday, January 1, 2018 | 10102000000 | 207761000 |
| Tuesday, January 1, 2019 | 10615000000 | 284812000 |
| Wednesday, January 1, 2020 | 8955000000 | 317875000 |
| Friday, January 1, 2021 | 9634000000 | 282660000 |
| Saturday, January 1, 2022 | 10042000000 | 451421000 |
| Sunday, January 1, 2023 | 10504000000 | 481871000 |
Infusing magic into the data realm
In the competitive landscape of pharmaceuticals, understanding the efficiency of Selling, General, and Administrative (SG&A) expenses is crucial. Over the past decade, Merck & Co., Inc. and Sarepta Therapeutics, Inc. have showcased contrasting strategies in managing these costs.
Merck, a giant in the industry, consistently reported SG&A expenses averaging around $10 billion annually from 2014 to 2023. Despite fluctuations, Merck's expenses remained relatively stable, reflecting a robust operational strategy. In contrast, Sarepta, a smaller player, saw its SG&A expenses grow from approximately $49 million in 2014 to nearly $482 million in 2023, marking a staggering increase of over 880%. This growth underscores Sarepta's aggressive expansion and investment in administrative capabilities.
These insights highlight the diverse approaches in managing operational costs, offering a glimpse into the strategic priorities of these pharmaceutical titans.
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and Merck & Co., Inc.
SG&A Efficiency Analysis: Comparing Merck & Co., Inc. and Novartis AG
Merck & Co., Inc. vs Regeneron Pharmaceuticals, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: Merck & Co., Inc. vs Merus N.V. Trends and Insights
Comparing SG&A Expenses: Merck & Co., Inc. vs Perrigo Company plc Trends and Insights
Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and Geron Corporation
Who Optimizes SG&A Costs Better? Merck & Co., Inc. or Iovance Biotherapeutics, Inc.
Comparing SG&A Expenses: Merck & Co., Inc. vs Evotec SE Trends and Insights
Breaking Down SG&A Expenses: Insmed Incorporated vs Sarepta Therapeutics, Inc.
Selling, General, and Administrative Costs: Sarepta Therapeutics, Inc. vs Madrigal Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Sarepta Therapeutics, Inc. vs TG Therapeutics, Inc.
Comparing SG&A Expenses: Sarepta Therapeutics, Inc. vs Viridian Therapeutics, Inc. Trends and Insights